Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
This clinical trial is for participants with diffuse midline glioma (DMG).
The purpose of this study is to better understand if cerebrospinal fluid (CSF) and blood obtained as a liquid biopsy correlates with disease status in patients with diffuse malignant gliomas. This study is being done because CSF and blood can provide critical information about the status of the diffuse midline glioma. Through the CSF and blood samples, researchers can detect molecules called cell-free DNA (cfDNA). These molecules can shed off from the tumor and are circulated in the CSF and blood. By analyzing cfDNA, researchers can have a better understanding on the status of the tumor.
This study will include the collection of CSF, blood samples, and implementation of the ventricular access device (VAD) for participants who have not already had a VAD implanted as part of their clinical care.
Participation in this research will last about 2 years including follow-up.
Detailed eligibility reviewed when participant contacts the study team.